47 results on '"Zinnhardt, Bastian"'
Search Results
2. Towards Optimized Bioavailability of 99mTc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity
- Author
-
Honold, Lisa, Austrup, Melanie, Faust, Andreas, Konken, Christian Paul, Schwegmann, Katrin, Zinnhardt, Bastian, Daniliuc, Constantin Gabriel, Haufe, Günter, Schäfers, Michael, Kopka, Klaus, and Hermann, Sven
- Published
- 2022
- Full Text
- View/download PDF
3. Imaging of the glioma microenvironment by TSPO PET
- Author
-
Zinnhardt, Bastian, Roncaroli, Federico, Foray, Claudia, Agushi, Erjon, Osrah, Bahiya, Hugon, Gaëlle, Jacobs, Andreas H., and Winkeler, Alexandra
- Published
- 2021
- Full Text
- View/download PDF
4. Characterization of the inflammatory post-ischemic tissue by full volumetric analysis of a multimodal imaging dataset
- Author
-
Barca, Cristina, Foray, Claudia, Hermann, Sven, Döring, Christian, Schäfers, Michael, Jacobs, Andreas H., and Zinnhardt, Bastian
- Published
- 2020
- Full Text
- View/download PDF
5. Somatostatin Receptor–Targeted Radioligand Therapy in Head and Neck Paraganglioma
- Author
-
Roll, Wolfgang, Müther, Michael, Sporns, Peter B., Zinnhardt, Bastian, Suero Molina, Eric, Seifert, Robert, Schäfers, Michael, Weckesser, Matthias, Stegger, Lars, Beule, Achim G., Stummer, Walter, and Rahbar, Kambiz
- Published
- 2020
- Full Text
- View/download PDF
6. [18F]DPA-714-PET-MRI reveals pronounced innate immunity in human anti-LGI1 and anti-CASPR2 limbic encephalitis.
- Author
-
Roll, Wolfgang, Bauer, Jan, Dik, Andre, Mueller, Christoph, Backhaus, Philipp, Räuber, Saskia, Zinnhardt, Bastian, Gallus, Marco, Wimberley, Catriona, Körtvelyessy, Peter, Schindler, Philipp, Stenzel, Werner, Elger, Christian E., Becker, Albert, Lewerenz, Jan, Wiendl, Heinz, Meuth, Sven G., Schäfers, Michael, and Melzer, Nico
- Subjects
EPILEPSY ,ANTI-NMDA receptor encephalitis ,NATURAL immunity ,ENCEPHALITIS ,SCIENCE education - Abstract
This document, published in the Journal of Neurology, explores the use of [18F]DPA-714-PET-MRI as a diagnostic tool for autoimmune limbic encephalitis (ALE) with specific autoantibodies. The study involved two patients with these autoantibodies, and the results showed increased tracer uptake in certain areas of the brain. The study suggests that [18F]DPA-714-PET-MRI could be a valuable tool for diagnosing ALE and assessing the immune response in the brain. However, further research is needed to fully understand its potential for clinical use in ALE. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
7. Initial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system
- Author
-
Backhaus, Philipp, Roll, Wolfgang, Beuker, Carolin, Zinnhardt, Bastian, Seifert, Robert, Wenning, Christian, Eisenblätter, Michel, Thomas, Christian, Schmidt-Pogoda, Antje, Strunk, Daniel, Wagner, Stefan, Faust, Andreas, Tüttelmann, Frank, Röpke, Albrecht, Jacobs, Andreas H., Stummer, Walter, Wiendl, Heinz, Meuth, Sven G., Schäfers, Michael, Grauer, Oliver, and Minnerup, Jens
- Published
- 2020
- Full Text
- View/download PDF
8. Translational imaging of TSPO reveals pronounced innate inflammation in human and murine CD8 T cell–mediated limbic encephalitis
- Author
-
Gallus, Marco, Roll, Wolfgang, Rolfes, Leoni, Wachsmuth, Lydia, Pitsch, Julika, Van Loo, Karen M. J., Räuber, Saskia, Okada, Hideho, Wimberley, Catriona, Strippel, Christine, Golombeck, Kristin S., Johnen, Andreas, Dik, Andre, Kovac, Stjepana, Groß, Catharina C., Backhaus, Philipp, Seifert, Robert, Lewerenz, Jan, Surges, Rainer, Elger, Christian E., Wiendl, Heinz, Ruck, Tobias, Becker, Albert J., Barca, Cristina, Faber, Cornelius, Jacobs, Andreas H., Bauer, Jan, Meuth, Sven G., Schäfers, Michael, Melzer, Nico, Zinnhardt, Bastian, Hicking, Gordon, Mueller, Christoph, Naik, Venu Narayanan, Anstötz, Max, and Krämer, Julia
- Subjects
Inflammation ,Neurosciences ,Mice ,GABA ,Clinical Research ,Limbic Encephalitis ,Positron-Emission Tomography ,Receptors ,Animals ,Humans ,Biomedical Imaging ,2.1 Biological and endogenous factors ,Aetiology ,Carrier Proteins - Abstract
Science advances 9(23), eabq7595 (2023). doi:10.1126/sciadv.abq7595, Published by American Association for the Advancement of Science, Washington, DC [u.a.]
- Published
- 2023
- Full Text
- View/download PDF
9. Preliminary results investigating synaptic density across the Alzheimer's Disease continuum.
- Author
-
Giorgio, Joseph, Soleimani‐Meigooni, David N., Chen, Xi, Toueg, Tyler N, Weimer, Robby, Zinnhardt, Bastian, Baker, Suzanne L., Janabi, Mustafa, Rabinovici, Gil D., and Jagust, William J.
- Abstract
Background: Progressive loss of synapses occurs throughout the Alzheimer's Disease (AD) continuum and is closely associated with cognitive impairment. Here, we present pilot data investigating variation in synaptic density across aging and AD using 18F‐SynVesT‐1 molecular imaging, a ligand for the SV2A site. Method: 26 participants underwent 18F‐SynVesT‐1 imaging to estimate synaptic density in‐vivo. Participants were young adults (Y) (n = 7; Age = 26.1+‐3.8; Sex(F) = 4), cognitively unimpaired older adults (O) (n = 13; Age = 79.7+‐4.27; Sex(F) = 7) or patients (P) (n = 6; Age = 66.3 +‐8.2; Sex (F) = 1; Diagnoses EOAD = 3, MCI = 1, PCA(AD) = 1; lvPPA(AD)). We collected a 90 min dynamic sequence after injection of 5 mCi of tracer. Participant whole brain Distribution Volume Ratio (DVR) images were generated using a cerebellar grey matter reference region. O and P groups also underwent tau and β‐amyloid (Aβ) PET imaging (O: 18F‐flortaucipir,11C‐PiB; P: 18F‐PI‐2620, 18F‐Florbetaben) and a visual assessment of tau and Aβ positivity for AD was determined by an expert reviewer (DSM). Result: We contrasted 18F‐SynVesT‐1 uptake in four cortical regions for Y, O and P. In each region, we observed a significant effect of group (Hippocampus F(1,23) = 4.35, p = 0.025 (uncorrected); Meta‐Temporal ROI F(1,23) = 4.36, p = 0.025 (uncorrected); Temporal F(1,23) = 9, p<0.01(FWE corrected); F(1,23) = 14.4, p<0.001 (FWE corrected)) Figure 1. Further, we observe non‐significant numerical differences suggesting lower synaptic density in participants with biomarker evidence of Aβ and tau Figure 1. Finally, we observe a positive partial correlation between temporal cortical thickness and temporal 18F‐SynVesT‐1 uptake controlling for age (r(23) = 0.54,p = 0.006) Figure 2. We observe no relationship between age and tracer uptake in the cerebral white matter (r(24) = ‐0.01,p = 0.95), suggesting the reference region selected does not introduce systematic biases in the DVR image. Conclusion: This demonstrates 18F‐SynVesT‐1 PET can capture age and AD related decreases in synaptic density across the cortex. Further, we show an association between cortical thickness and synaptic density in the temporal cortex controlling for biases due to age. Future work will incorporate additional participants and investigate participant level associations between regional 18F‐SynVesT‐1 uptake, cognition, and in‐vivo AD pathologies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Intrathecal versus Peripheral Inflammatory Protein Profile in MS Patients at Diagnosis: A Comprehensive Investigation on Serum and CSF.
- Author
-
Pezzini, Francesco, Pisani, Annalisa, Mazziotti, Valentina, Marastoni, Damiano, Tamanti, Agnese, Borroni, Edilio, Magon, Stefano, Zinnhardt, Bastian, Magliozzi, Roberta, and Calabrese, Massimiliano
- Subjects
CEREBROSPINAL fluid examination ,DIAGNOSIS ,CEREBROSPINAL fluid ,BLOOD proteins ,BLOOD serum analysis ,MULTIPLE sclerosis ,SPINAL cord - Abstract
Intrathecal inflammation plays a key role in the pathogenesis of multiple sclerosis (MS). To better elucidate its relationship with peripheral inflammation, we investigated the correlation between cerebrospinal fluid (CSF) and serum levels of 61 inflammatory proteins. Paired CSF and serum samples were collected from 143 treatment-naïve MS patients at diagnosis. A customized panel of 61 inflammatory molecules was analyzed by a multiplex immunoassay. Correlations between serum and CSF expression levels for each molecule were performed by Spearman's method. The expression of sixteen CSF proteins correlated with their serum expression (p-value < 0.001): only five molecules (CXCL9, sTNFR2, IFNα2, Pentraxin-3, and TSLP) showed a Rho value >0.40, suggesting moderate CSF/serum correlation. No correlation between inflammatory serum patterns and Q
alb was observed. Correlation analysis of serum expression levels of these sixteen proteins with clinical and MRI parameters pinpointed a subset of five molecules (CXCL9, sTNFR2, IFNα2, IFNβ, and TSLP) negatively correlating with spinal cord lesion volume. However, following FDR correction, only the correlation of CXCL9 remained significant. Our data support the hypothesis that the intrathecal inflammation in MS only partially associates with the peripheral one, except for the expression of some immunomodulators that might have a key role in the initial MS immune response. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
11. Impact of a multi-nutrient diet on cognition, brain metabolism, hemodynamics, and plasticity in apoE4 carrier and apoE knockout mice
- Author
-
Jansen, Diane, Zerbi, Valerio, Janssen, Carola I. F., van Rooij, Daan, Zinnhardt, Bastian, Dederen, Pieter J., Wright, Alan J., Broersen, Laus M., Lütjohann, Dieter, Heerschap, Arend, and Kiliaan, Amanda J.
- Published
- 2014
- Full Text
- View/download PDF
12. Interrogating glioma-associated microglia/macrophage dynamics under CSF-1R therapy with multi-tracer in vivo PET/MR imaging.
- Author
-
Foray, Claudia, Barca, Cristina, Winkeler, Alexandra, Wagner, Stefan, Hermann, Sven, Schäfers, Michael, Grauer, Oliver M., Zinnhardt, Bastian, and Jacobs, Andreas H.
- Published
- 2022
- Full Text
- View/download PDF
13. Short-term colony stimulating factor-1 receptor inhibition-induced repopulation after stroke assessed by longitudinal 18F-DPA-714 PET imaging.
- Author
-
Barca, Cristina, Kiliaan, Amanda J., Wachsmuth, Lydia, Foray, Claudia, Hermann, Sven, Faber, Cornelius, Schäfers, Michael, Wiesmann, Maximilian, Zinnhardt, Bastian, and Jacobs, Andreas H.
- Published
- 2022
- Full Text
- View/download PDF
14. Multimodal Imaging Reveals Temporal and Spatial Microglia and Matrix Metalloproteinase Activity after Experimental Stroke
- Author
-
Zinnhardt, Bastian, Viel, Thomas, Wachsmuth, Lydia, Vrachimis, Alexis, Wagner, Stefan, Breyholz, Hans-Jörg, Faust, Andreas, Hermann, Sven, Kopka, Klaus, Faber, Cornelius, Dollé, Frédéric, Pappata, Sabina, Planas, Anna M, Tavitian, Bertrand, Schäfers, Michael, Sorokin, Lydia M, Kuhlmann, Michael T, and Jacobs, Andreas H
- Published
- 2015
- Full Text
- View/download PDF
15. Chapter 78 - Imaging of Gene and Cell-Based Therapies: Basis and Clinical Trials
- Author
-
Jacobs, Andreas H., Schelhaas, Sonja, Viel, Thomas, Waerzeggers, Yannic, Winkeler, Alexandra, Zinnhardt, Bastian, and Gelovani, Juri
- Published
- 2021
- Full Text
- View/download PDF
16. In Vivo Quantitative Imaging of Glioma Heterogeneity Employing Positron Emission Tomography.
- Author
-
Barca, Cristina, Foray, Claudia, Zinnhardt, Bastian, Winkeler, Alexandra, Herrlinger, Ulrich, Grauer, Oliver M., and Jacobs, Andreas H.
- Subjects
IN vivo studies ,GLIOMAS ,POSITRON emission tomography - Abstract
Simple Summary: Defining glioma heterogeneity represents a promising strategy to unravel the mechanisms behind therapy resistance and tumor recurrence. The current review provides a comprehensive overview of experimental and clinical data concerning the visualization and quantification of the tumor microenvironment heterogeneity using molecular imaging, with a special emphasis on positron emission tomography (PET). Glioblastoma is the most common primary brain tumor, highly aggressive by being proliferative, neovascularized and invasive, heavily infiltrated by immunosuppressive glioma-associated myeloid cells (GAMs), including glioma-associated microglia/macrophages (GAMM) and myeloid-derived suppressor cells (MDSCs). Quantifying GAMs by molecular imaging could support patient selection for GAMs-targeting immunotherapy, drug target engagement and further assessment of clinical response. Magnetic resonance imaging (MRI) and amino acid positron emission tomography (PET) are clinically established imaging methods informing on tumor size, localization and secondary phenomena but remain quite limited in defining tumor heterogeneity, a key feature of glioma resistance mechanisms. The combination of different imaging modalities improved the in vivo characterization of the tumor mass by defining functionally distinct tissues probably linked to tumor regression, progression and infiltration. In-depth image validation on tracer specificity, biological function and quantification is critical for clinical decision making. The current review provides a comprehensive overview of the relevant experimental and clinical data concerning the spatiotemporal relationship between tumor cells and GAMs using PET imaging, with a special interest in the combination of amino acid and translocator protein (TSPO) PET imaging to define heterogeneity and as therapy readouts. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Towards Optimized Bioavailability of 99mTc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity.
- Author
-
Honold, Lisa, Austrup, Melanie, Faust, Andreas, Konken, Christian Paul, Schwegmann, Katrin, Zinnhardt, Bastian, Daniliuc, Constantin Gabriel, Haufe, Günter, Schäfers, Michael, Kopka, Klaus, and Hermann, Sven
- Abstract
Introduction: Dysregulated activity of matrix metalloproteinases (MMPs) drives a variety of pathophysiological conditions. Non-invasive imaging of MMP activity in vivo promises diagnostic and prognostic value. However, current targeting strategies by small molecules are typically limited with respect to the bioavailability of the labeled MMP binders in vivo. To this end, we here introduce and compare three chemical modifications of a recently developed barbiturate-based radiotracer with respect to bioavailability and potential to image MMP activity in vivo.Methods: Barbiturate-based MMP inhibitors with an identical targeting unit but varying hydrophilicity were synthesized, labeled with technetium-99m, and evaluated in vitro and in vivo. Biodistribution and radiotracer elimination were determined in C57/BL6 mice by serial SPECT imaging. MMP activity was imaged in a MMP-positive subcutaneous xenograft model of human K1 papillary thyroid tumors. In vivo data were validated by scintillation counting, autoradiography, and MMP immunohistochemistry.Results: We prepared three new 99mTc-labeled MMP inhibitors, bearing either a glycine ([99mTc]MEA39), lysine ([99mTc]MEA61), or the ligand HYNIC with the ionic co-ligand TPPTS ([99mTc]MEA223) yielding gradually increasing hydrophilicity. [99mTc]MEA39 and [99mTc]MEA61 were rapidly eliminated via hepatobiliary pathways. In contrast, [99mTc]MEA223 showed delayed in vivo clearance and primary renal elimination. In a thyroid tumor xenograft model, only [99mTc]MEA223 exhibited a high tumor-to-blood ratio that could easily be delineated in SPECT images.Conclusion: Introduction of HYNIC/TPPTS into the barbiturate lead structure ([99mTc]MEA223) results in delayed renal elimination and allows non-invasive MMP imaging with high signal-to-noise ratios in a papillary thyroid tumor xenograft model. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
18. The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke).
- Author
-
Barca, Cristina, Foray, Claudia, Hermann, Sven, Herrlinger, Ulrich, Remory, Isabel, Laoui, Damya, Schäfers, Michael, Grauer, Oliver M., Zinnhardt, Bastian, and Jacobs, Andreas H.
- Abstract
Immunomodulatory therapies have fueled interest in targeting microglial cells as part of the innate immune response after infection or injury. In this context, the colony-stimulating factor 1 (CSF-1) and its receptor (CSF-1R) have gained attention in various neurological conditions to deplete and reprogram the microglia/macrophages compartment. Published data in physiological conditions support the use of small-molecule inhibitors to study microglia/macrophages dynamics under inflammatory conditions and as a therapeutic strategy in pathologies where those cells support disease progression. However, preclinical and clinical data highlighted that the complexity of the spatiotemporal inflammatory response could limit their efficiency due to compensatory mechanisms, ultimately leading to therapy resistance. We review the current state-of-art in the field of CSF-1R inhibition in glioma and stroke and provide an overview of the fundamentals, ongoing research, potential developments of this promising therapeutic strategy and further application toward molecular imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. A longitudinal PET/MR imaging study of colony stimulating factor-1 receptor-mediated microglia depletion in experimental stroke.
- Author
-
Barca, Cristina, Kiliaan, Amanda J., Foray, Claudia, Wachsmuth, Lydia, Hermann, Sven, Faber, Cornelius, Schäfers, Michael, Wiesmann, Maximilian, Jacobs, Andreas H., and Zinnhardt, Bastian
- Published
- 2021
- Full Text
- View/download PDF
20. TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma Running title: Imaging glioma infiltration
- Author
-
Pigeon, Hayet, Pérès, Elodie A., Truillet, Charles, Jego, Benoît, Boumezbeur, Fawzi, Caillé, Fabien, Zinnhardt, Bastian, Jacobs, Andreas, Le Bihan, Denis, Winkeler, Alexandra, Imagerie Moléculaire in Vivo (IMIV - U1023 - ERL9218), Service Hospitalier Frédéric Joliot (SHFJ), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales (ISTCT), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service NEUROSPIN (NEUROSPIN), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Hypoxie, physiopathologies cérébrovasculaire et tumorale (CERVOxy), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), ANR-11-INBS-0006,FLI,France Life Imaging(2011), European Project: 278850,EC:FP7:HEALTH,FP7-HEALTH-2011-two-stage,INMIND(2012), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Le Roy, Léna, Infrastructures - France Life Imaging - - FLI2011 - ANR-11-INBS-0006 - INBS - VALID, and Imaging of Neuroinflammation in Neurodegenerative Diseases - INMIND - - EC:FP7:HEALTH2012-03-01 - 2017-02-28 - 278850 - VALID
- Subjects
[SDV] Life Sciences [q-bio] ,diffusion MRI ,S-index ,glioma ,[18F]DPA-714 ,[SDV]Life Sciences [q-bio] ,TSPO - Abstract
CERVOXY COLL; International audience
- Published
- 2019
21. Impact of hydroxytyrosol on stroke: tracking therapy response on neuroinflammation and cerebrovascular parameters using PET-MR imaging and on functional outcomes.
- Author
-
Barca, Cristina, Wiesmann, Maximilian, Calahorra, Jesús, Wachsmuth, Lydia, Döring, Christian, Foray, Claudia, Heiradi, Ali, Hermann, Sven, Peinado, Maria Ángeles, Siles, Eva, Faber, Cornelius, Schäfers, Michael, Kiliaan, Amanda J., Jacobs, Andreas H., and Zinnhardt, Bastian
- Published
- 2021
- Full Text
- View/download PDF
22. Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma.
- Author
-
Valtorta, Silvia, Lo Dico, Alessia, Raccagni, Isabella, Martelli, Cristina, Pieri, Valentina, Rainone, Paolo, Todde, Sergio, Zinnhardt, Bastian, De Bernardi, Elisabetta, Coliva, Angela, Politi, Letterio S., Viel, Thomas, Jacobs, Andreas H., Galli, Rossella, Ottobrini, Luisa, Vaira, Valentina, and Moresco, Rosa Maria
- Subjects
TRANSLOCATOR proteins ,POSITRON emission tomography ,GLIOBLASTOMA multiforme ,EPIDERMAL growth factor receptors ,CELLULAR therapy ,METFORMIN - Abstract
Glioblastoma (GBM) is a highly aggressive tumor of the brain. Despite the efforts, response to current therapies is poor and 2-years survival rate ranging from 6-12%. Here, we evaluated the preclinical efficacy of Metformin (MET) as add-on therapy to Temozolomide (TMZ) and the ability of [
18 F]FLT (activity of thymidine kinase 1 related to cell proliferation) and [18 F]VC701 (translocator protein, TSPO) Positron Emission Tomography (PET) radiotracers to predict tumor response to therapy. Indeed, TSPO is expressed on the outer mitochondrial membrane of activated microglia/macrophages, tumor cells, astrocytes and endothelial cells. TMZ-sensitive (Gli36ΔEGFR-1 and L0627) or -resistant (Gli36ΔEGFR-2) GBM cell lines representative of classical molecular subtype were tested in vitro and in vivo in orthotopic mouse models. Our results indicate that in vitro , MET increased the efficacy of TMZ on TMZ-sensitive and on TMZ-resistant cells by deregulating the balance between pro-survival (bcl2) and pro-apoptotic (bax/bad) Bcl-family members and promoting early apoptosis in both Gli36ΔEGFR-1 and Gli36ΔEGFR-2 cells. In vivo , MET add-on significantly extended the median survival of tumor-bearing mice compared to TMZ-treated ones and reduced the rate of recurrence in the TMZ-sensitive models. PET studies with the cell proliferation radiopharmaceutical [18 F]FLT performed at early time during treatment were able to distinguish responder from non-responder to TMZ but not to predict the duration of the effect. On the contrary, [18 F]VC701 uptake was reduced only in mice treated with MET plus TMZ and levels of uptake negatively correlated with animals' survival. Overall, our data showed that MET addition improved TMZ efficacy in GBM preclinical models representative of classical molecular subtype increasing survival time and reducing tumor relapsing rate. Finally, results from PET imaging suggest that the reduction of cell proliferation represents a common mechanism of TMZ and combined treatment, whereas only the last was able to reduce TSPO. This reduction was associated with the duration of treatment response. TSPO-ligand may be used as a complementary molecular imaging marker to predict tumor microenvironment related treatment effects. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
23. Imaging temozolomide-induced changes in the myeloid glioma microenvironment.
- Author
-
Foray, Claudia, Valtorta, Silvia, Barca, Cristina, Winkeler, Alexandra, Roll, Wolfgang, Müther, Michael, Wagner, Stefan, Gardner, Miranda L., Hermann, Sven, Schäfers, Michael, Grauer, Oliver Martin, Moresco, Rosa Maria, Zinnhardt, Bastian, and Jacobs, Andreas H.
- Published
- 2021
- Full Text
- View/download PDF
24. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
- Author
-
Müther, Michael, Roll, Wolfgang, Brokinkel, Benjamin, Zinnhardt, Bastian, Sporns, Peter B., Seifert, Robert, Schäfers, Michael, Weckesser, Matthias, Stegger, Lars, Stummer, Walter, and Rahbar, Kambiz
- Published
- 2020
- Full Text
- View/download PDF
25. Contributors
- Author
-
Aarntzen, Erik, Achilefu, Samuel, Akam, Eman A., Albaghdadi, Mazen, Beer, Ambros J., Bharti, Santosh, Bhujwalla, Zaver M., Bischof, Gérard N., Biswal, Sandip, Boss, Marti, Botnar, René M., Brinson, Zabecca, Brom, Maarten, Buitinga, Mijke, Bulte, Jeff W.M., Caravan, Peter, Chan, Heang-Ping, Chandy, Mark, Chaney, Aisling M., Chen, Delphine L., Chen, Xiaoyuan (Shawn), Chenevert, Thomas L., Coughlin, Jennifer M., Covington, Matthew F., Cumming, Paul, Daldrup-Link, Heike E., Deal, Emily M., de Galan, Bastiaan, Derlin, Thorsten, Dewhirst, Mark W., Di Paolo, Arianna, Drzezga, Alexander, Du, Yong, Thi-Quynh Duong, Mai, Ehman, Richard L., Eriksson, Olof, Galli, Filippo, Gatenby, Robert A., Gelovani, Juri, Giehl, Kathrin, Giger, Maryellen L., Goel, Reema, Gold, Garry, Gotthardt, Martin, Graham, Michael M., Gropler, Robert J., Gründer, Gerhard, Gulhane, Avanti, Hadjiiski, Lubomir, Hajhosseiny, Reza, Hammoud, Dima A., Helfer, Brooke M., Hicks, Rodney J., Higuchi, Takahiro, Hoffman, John M., Honer, Michael, Huang, Sung-Cheng (Henry), Hung, Jessica, Hwang, Do Won, Jackson, Isaac M., Jacobs, Andreas H., Jaffer, Farouc A., Jain, Sanjay K., James, Michelle L., Jansen, Tom, Johansson, Lars, Joosten, Lieke, Kakkad, Samata, Kamson, David, Kang, Sae-Ryung, Kelly, Kimberly A., Knopp, Michelle I., Knopp, Michael V., Kogan, Feliks, Krishnamachary, Balaji, Künnecke, Basil, Lee, Dong Soo, Libby, Peter, Luker, Gary D., Luker, Kathryn E., Makowski, Marcus R., Mankoff, David A., Massoud, Tarik F., Meyer, Charles R., Miller, Zach, Min, Jung-Joon, Mondal, Suman B., Montesi, Sydney B., Navin, Patrick J., Nekolla, Stephan G., Niu, Gang, Notohamiprodjo, Susan, Ordoñez, Alvaro A., Osborn, Eric A., Pacheco-Torres, Jesus, Pagano, Gennaro, Palmer, Gregory M., Paulmurugan, Ramasamy, Penet, Marie-France, Phinikaridou, Alkystis, Pomper, Martin G., Prieto, Claudia, Qi, Haikun, Raghunand, Natarajan, Ramar, Thangam, Reynolds, Fred, Ropella-Panagis, Kathleen, Ross, Brian D., Rowe, Steven P., Rudin, Markus, Sadaghiani, Mohammad S., Sager, Hendrik, Samala, Ravi, Saraste, Antti, Schelhaas, Sonja, Schwaiger, Markus, Schwarz, Sally W., Seiberlich, Nicole, Shapiro, Mikhail G., Shim, Hyunsuk, Signore, Alberto, Solnes, Lilja B., Suh, Minseok, Tsien, Christina, van Eimeren, Thilo, Varasteh, Zohreh, Venkatesh, Sudhakar Kundapur, Viel, Thomas, Waerzeggers, Yannic, Wahl, Richard L., Weber, Wolfgang, Werner, Rudolf A., Winkeler, Alexandra, Wong, Dean F., Wright, Chadwick L., Wu, Anna M., Wu, Joseph C., Yoon, Daehyun, You, Sung-Hwan, Yuan, Chun, Yuan, Hong, Zanzonico, Pat, Zhao, Xue-Qiao, Zhou, Iris Y., and Zinnhardt, Bastian
- Published
- 2021
- Full Text
- View/download PDF
26. TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma.
- Author
-
Zinnhardt, Bastian, Müther, Michael, Roll, Wolfgang, Backhaus, Philipp, Jeibmann, Astrid, Foray, Claudia, Barca, Cristina, Döring, Christian, Tavitian, Bertrand, Dollé, Frédéric, Weckesser, Matthias, Winkeler, Alexandra, Hermann, Sven, Wagner, Stefan, Wiendl, Heinz, Stummer, Walter, Jacobs, Andreas H, Schäfers, Michael, and Grauer, Oliver M
- Published
- 2020
- Full Text
- View/download PDF
27. Effect of a multinutrient intervention after ischemic stroke in female C57Bl/6 mice.
- Author
-
Wiesmann, Maximilian, Timmer, Nienke M., Zinnhardt, Bastian, Reinhard, Dirk, Eligehausen, Sarah, Königs, Anja, Ben Jeddi, Hasnae, Dederen, Pieter J., Jacobs, Andreas H., and Kiliaan, Amanda J.
- Subjects
CORONARY disease ,STROKE ,MAGNETIC resonance imaging ,IMMUNOHISTOCHEMISTRY ,CEREBROVASCULAR disease - Abstract
Abstract: Stroke can affect females very differently from males, and therefore preclinical research on underlying mechanisms and the effects of interventions should not be restricted to male subjects, and treatment strategies for stroke should be tailored to benefit both sexes. Previously, we demonstrated that a multinutrient intervention (Fortasyn) improved impairments after ischemic stroke induction in male C57Bl/6 mice, but the therapeutic potential of this dietary treatment remained to be investigated in females. We now induced a transient middle cerebral artery occlusion (tMCAo) in C57Bl/6 female mice and immediately after surgery switched to either Fortasyn or an isocaloric Control diet. The stroke females performed several behavioral and motor tasks before and after tMCAo and were scanned in an 11.7 Tesla magnetic resonance imaging (MRI) scanner to assess brain perfusion, integrity, and functional connectivity. To assess brain plasticity, inflammation, and vascular integrity, immunohistochemistry was performed after killing of the mice. We found that the multinutrient intervention had diverse effects on the stroke‐induced impairments in females. Similar to previous observations in male stroke mice, brain integrity, sensorimotor integration and neurogenesis benefitted from Fortasyn, but impairments in activity and motor skills were not improved in female stroke mice. Overall, Fortasyn effects in the female stroke mice seem more modest in comparison to previously investigated male stroke mice. We suggest that with further optimization of treatment protocols more information on the efficacy of specific interventions in stroked females can be gathered. This in turn will help with the development of (gender‐specific) treatment regimens for cerebrovascular diseases such as stroke. This article is part of the Special Issue “Vascular Dementia”. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
28. In vivo bioluminescence imaging of neurogenesis - the role of the blood brain barrier in an experimental model of Parkinson's disease.
- Author
-
Fricke, Inga B., Schelhaas, Sonja, Zinnhardt, Bastian, Viel, Thomas, Hermann, Sven, Couillard‐Després, Sébastien, Jacobs, Andreas H., and Bolam, Paul
- Subjects
BIOLUMINESCENCE assay ,DEVELOPMENTAL neurobiology ,PARKINSON'S disease ,TRANSGENIC mice ,BRAIN injuries - Abstract
Bioluminescence imaging in transgenic mice expressing firefly luciferase in Doublecortin
+ (Dcx) neuroblasts might serve as a powerful tool to study the role of neurogenesis in models of brain injury and neurodegeneration using non-invasive, longitudinal in vivo imaging. Therefore, we aimed to use BLI in B6(Cg)-Tyrc-2J/J Dcx-Luc (Doublecortin-Luciferase, Dcx-Luc) mice to investigate its suitability to assess neurogenesis in a unilateral injection model of Parkinson's disease. We further aimed to assess the blood brain barrier leakage associated with the intranigral 6- OHDA injection to evaluate its impact on substrate delivery and bioluminescence signal intensity. Two weeks after lesion, we observed an increase in bioluminescence signal in the ipsilateral hippocampal region in both, 6- OHDA and vehicle injected Dcx-Luc mice. At the same time, no corresponding increase in Dcx+ neuroblast numbers could be observed in the dentate gyrus of C57Bl6 mice. Blood brain barrier leakage was observed in the hippocampal region and in the degenerating substantia nigra of C57Bl6 mice in vivo using T1 weighted Magnetic Resonance Imaging with Gadovist® and ex vivo using Evans Blue Fluorescence Reflectance Imaging and mouse Immunoglobulin G staining. Our data suggests a BLI signal dependency on blood brain barrier permeability, underlining a major pitfall of substrate/tracer dependent imaging in invasive disease models. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
29. Multimodal Imaging of Patients With Gliomas Confirms 11C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy.
- Author
-
Laukamp, Kai R., Lindemann, Florian, Weckesser, Matthias, Hesselmann, Volker, Ligges, Sandra, Woölfer, Johannes, Jeibmann, Astrid, Zinnhardt, Bastian, Viel, Thomas, Schäfers, Michael, Paulus, Werner, Stummer, Walter, Schober, Otmar, and Jacobs, Andreas H.
- Subjects
GLIOMAS ,TUMOR grading ,MAGNETIC resonance imaging ,VISUALIZATION ,LOGISTIC regression analysis - Abstract
The value of combined L-(methyl-[
11 C])methionine positron-emitting tomography (MET-PET) and magnetic resonance imaging (MRI) with regard to tumor extent, entity prediction, and therapy effects in clinical routine in patients with suspicion of a brain tumor was investigated. In n = 65 patients with histologically verified brain lesions n = 70MET-PET andMRI (T1-weighted gadolinium-enhanced [T1w-Gd] and fluid-attenuated inversion recovery or T2-weighted [FLAIR/T2w]) examinations were performed. The computer software "visualization and analysis framework volume rendering engine (Voreen)" was used for analysis of extent and intersection of tumor compartments. Binary logistic regression models were developed to differentiate between World Health Organization (WHO) tumor types/grades. Tumor sizes as defined by thresholding based on tumor-to-background ratios were significantly different as determined byMET-PET (21.6±36.8 cm3 ), T1w-Gd-MRI (3.9±7.8 cm3 ), and FLAIR/T2-MRI (64.8±60.4 cm3 ; P < .001). The METPET visualized tumor activity where MRI parameters were negative: PET positive tumor volume without Gd enhancement was 19.8± 35.0 cm3 and without changes in FLAIR/T2 10.3±25.7 cm3 . FLAIR/T2-MRI visualized greatest tumor extent with differences to METPET being greater in posttherapy (64.6±62.7 cm3 ) than in newly diagnosed patients (20.5±52.6 cm3 ). The binary logistic regression model differentiated between WHO tumor types (fibrillary astrocytoma II n=10 fromother gliomas n=16) with an accuracy of 80.8% in patients at primary diagnosis. Combined PET and MRI improve the evaluation of tumor activity, extent, type/grade prediction, and therapy-induced changes in patients with glioma and serve information highly relevant for diagnosis and management. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
30. Letter to the editor regarding "Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials".
- Author
-
Schulte-Mecklenbeck, Andreas, Zinnhardt, Bastian, Müller-Miny, Louisa, Haessner, Svea, Meyer zu Hörste, Gerd, Wiendl, Heinz, and Gross, Catharina C.
- Subjects
- *
CEREBROSPINAL fluid , *CLINICAL trials , *LEUCOCYTES - Published
- 2023
- Full Text
- View/download PDF
31. Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.
- Author
-
Barca, Cristina, Griessinger, Christoph M., Faust, Andreas, Depke, Dominic, Essler, Markus, Windhorst, Albert D., Devoogdt, Nick, Brindle, Kevin M., Schäfers, Michael, Zinnhardt, Bastian, and Jacobs, Andreas H.
- Subjects
SINGLE-photon emission computed tomography ,TUMOR diagnosis ,POSITRON emission tomography ,RADIOPHARMACEUTICALS ,PROSTATE ,NUCLEAR medicine ,THYROID gland - Abstract
Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Translational imaging of TSPO reveals pronounced innate inflammation in human and murine CD8 T cell-mediated limbic encephalitis.
- Author
-
Gallus M, Roll W, Dik A, Barca C, Zinnhardt B, Hicking G, Mueller C, Naik VN, Anstötz M, Krämer J, Rolfes L, Wachsmuth L, Pitsch J, van Loo KMJ, Räuber S, Okada H, Wimberley C, Strippel C, Golombeck KS, Johnen A, Kovac S, Groß CC, Backhaus P, Seifert R, Lewerenz J, Surges R, Elger CE, Wiendl H, Ruck T, Becker AJ, Faber C, Jacobs AH, Bauer J, Meuth SG, Schäfers M, and Melzer N
- Subjects
- Animals, Humans, Mice, Carrier Proteins metabolism, Inflammation metabolism, Positron-Emission Tomography methods, Receptors, GABA metabolism, Limbic Encephalitis diagnostic imaging
- Abstract
Autoimmune limbic encephalitis (ALE) presents with new-onset mesial temporal lobe seizures, progressive memory disturbance, and other behavioral and cognitive changes. CD8 T cells are considered to play a key role in those cases where autoantibodies (ABs) target intracellular antigens or no ABs were found. Assessment of such patients presents a clinical challenge, and novel noninvasive imaging biomarkers are urgently needed. Here, we demonstrate that visualization of the translocator protein (TSPO) with [
18 F]DPA-714-PET-MRI reveals pronounced microglia activation and reactive gliosis in the hippocampus and amygdala of patients suspected with CD8 T cell ALE, which correlates with FLAIR-MRI and EEG alterations. Back-translation into a preclinical mouse model of neuronal antigen-specific CD8 T cell-mediated ALE allowed us to corroborate our preliminary clinical findings. These translational data underline the potential of [18 F]DPA-714-PET-MRI as a clinical molecular imaging method for the direct assessment of innate immunity in CD8 T cell-mediated ALE.- Published
- 2023
- Full Text
- View/download PDF
33. Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI.
- Author
-
Foray C, Barca C, Winkeler A, Wagner S, Hermann S, Schäfers M, Grauer OM, Zinnhardt B, and Jacobs AH
- Subjects
- Acetamides metabolism, Amines metabolism, Amino Acids metabolism, Animals, Fluorine Radioisotopes metabolism, Macrophage Colony-Stimulating Factor metabolism, Macrophages metabolism, Magnetic Resonance Imaging, Mice, Mice, Inbred C57BL, Microglia pathology, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Pyrimidines metabolism, Pyrimidines pharmacology, Receptor Protein-Tyrosine Kinases metabolism, Brain Neoplasms metabolism, Glioma diagnostic imaging, Glioma drug therapy, Glioma metabolism
- Abstract
Glioma-associated microglia and macrophages (GAMMs) are key players in creating an immunosuppressive microenvironment. They can be efficiently targeted by inhibiting the colony-stimulating factor 1 receptor (CSF-1R). We applied noninvasive PET/CT and PET/MRI using
18 F-fluoroethyltyrosine (18 F-FET) (amino acid metabolism) and N,N -diethyl-2-[4-(2-18 F-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5- a ]pyrimidine-3-acetamide (18 F-DPA-714) (translocator protein) to understand the role of GAMMs in glioma initiation, monitor in vivo therapy-induced GAMM depletion, and observe GAMM repopulation after drug withdrawal. Methods: C57BL/6 mice ( n = 44) orthotopically implanted with syngeneic mouse GL261 glioma cells were treated with different regimens using the CSF-1R inhibitor PLX5622 (6-fluoro- N -((5-fluoro-2-methoxypyridin-3-yl)methyl)-5-((5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)pyridin-2-amine) or vehicle, establishing a preconditioning model and a repopulation model, respectively. The mice underwent longitudinal PET/CT and PET/MRI. Results: The preconditioning model indicated similar tumor growth based on MRI (44.5% ± 24.8%),18 F-FET PET (18.3% ± 11.3%), and18 F-DPA-714 PET (16% ± 19.04%) volume dynamics in all groups, suggesting that GAMMs are not involved in glioma initiation. The repopulation model showed significantly reduced18 F-DPA-714 uptake (-45.6% ± 18.4%), significantly reduced GAMM infiltration even after repopulation, and a significantly decreased tumor volume (-54.29% ± 8.6%) with repopulation as measured by MRI, supported by a significant reduction in18 F-FET uptake (-50.2% ± 5.3%). Conclusion:18 F-FET and18 F-DPA-714 PET/MRI allow noninvasive assessment of glioma growth under various regimens of CSF-1R therapy. CSF-1R-mediated modulation of GAMMs may be of high interest as therapy or cotherapy against glioma., (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2022
- Full Text
- View/download PDF
34. Short-Term Colony-Stimulating Factor 1 Receptor Inhibition-Induced Repopulation After Stroke Assessed by Longitudinal 18 F-DPA-714 PET Imaging.
- Author
-
Barca C, Kiliaan AJ, Wachsmuth L, Foray C, Hermann S, Faber C, Schäfers M, Wiesmann M, Zinnhardt B, and Jacobs AH
- Subjects
- Acetamides metabolism, Animals, Calcium metabolism, Carrier Proteins metabolism, Infarction metabolism, Macrophage Colony-Stimulating Factor metabolism, Mice, Mice, Inbred C57BL, Microglia metabolism, Organic Chemicals, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography methods, Pyrazoles, Pyrimidines metabolism, Pyrimidines pharmacology, Fluorine Radioisotopes metabolism, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor antagonists & inhibitors, Stroke diagnostic imaging, Stroke drug therapy, Stroke metabolism
- Abstract
Studies on colony-stimulating factor 1 receptor (CSF-1R) inhibition-induced microglia depletion indicated that inhibitor withdrawal allowed the renewal of the microglia compartment via repopulation and resolved the inflammatory imbalance. Therefore, we investigated for the first time (to our knowledge) the effects of microglia repopulation on inflammation and functional outcomes in an ischemic mouse model using translocator protein (TSPO)-PET/CT and MR imaging, ex vivo characterization, and behavioral tests. Methods: Eight C57BL/6 mice per group underwent a 30-min transient occlusion of the middle cerebral artery. The treatment group received CSF-1R inhibitor in 1,200 ppm PLX5622 chow (Plexxikon Inc.) from days 3 to 7 to induce microglia/macrophage depletion and then went back to a control diet to allow repopulation. The mice underwent T2-weighted MRI on day 1 after ischemia and
18 F-labeled N,N -diethyl-2-(2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-α]pyrimidine-3-yl)acetamide (18 F-DPA-714) (TSPO) PET/CT on days 7, 14, 21, and 30. The percentage injected tracer dose per milliliter within the infarct, contralateral striatum, and spleen was assessed. Behavioral tests were performed to assess motor function recovery. Brains were harvested on days 14 and 35 after ischemia for ex vivo analyses (immunoreactivity and real-time quantitative polymerase chain reaction) of microglia- and macrophage-related markers. Results: Repopulation significantly increased18 F-DPA-714 uptake within the infarct on days 14 ( P < 0.001) and 21 ( P = 0.002) after ischemia. On day 14, the ionized calcium binding adaptor molecule 1 (Iba-1)-positive cell population showed significantly higher expression of TSPO, CSF-1R, and CD68, in line with microglia repopulation. Gene expression analyses on day 14 indicated a significant increase in microglia-related markers ( csf-1r, aif1, and p2ry12 ) with repopulation, whereas peripheral cell recruitment-related gene expression decreased ( cx3cr1 and ccr2 ), indicative of peripheral recruitment during CSF-1R inhibition. Similarly, uncorrected spleen uptake was significantly higher on day 7 after ischemia with treatment ( P = 0.001) and decreased after drug withdrawal. PLX5622-treated mice walked a longer distance ( P < 0.001) and more quickly ( P = 0.009), and showed greater forelimb strength ( P < 0.001), than control mice on day 14. Conclusion: This study highlighted the potential of18 F-DPA-714 PET/CT imaging to track microglia and macrophage repopulation after short-term CSF-1R inhibition in stroke., (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2022
- Full Text
- View/download PDF
35. A Longitudinal PET/MRI Study of Colony-Stimulating Factor 1 Receptor-Mediated Microglia Depletion in Experimental Stroke.
- Author
-
Barca C, Kiliaan AJ, Foray C, Wachsmuth L, Hermann S, Faber C, Schäfers M, Wiesmann M, Jacobs AH, and Zinnhardt B
- Subjects
- Animals, Carrier Proteins metabolism, Infarction metabolism, Macrophage Colony-Stimulating Factor metabolism, Magnetic Resonance Imaging methods, Mice, Mice, Inbred C57BL, Positron-Emission Tomography methods, Microglia metabolism, Stroke diagnostic imaging, Stroke drug therapy, Stroke metabolism
- Abstract
Microglia-induced neuroinflammation after stroke contributes to the exacerbation of postischemic damage but also supports neurorestorative events. Longitudinal molecular imaging of microglia-targeted therapies will support the assessment of target engagement, therapy efficacy, and deciphering of the mode of action. We investigated the effects of chronic colony-stimulating factor 1 receptor (CSF-1R) inhibitor-mediated microglia depletion on translocator protein (TSPO)-dependent neuroinflammation and cerebrovascular parameters using PET/MRI. Methods: Forty C57BL/6 mice underwent a 30-min transient occlusion of the middle cerebral artery and were randomly assigned to either a control group or a group treated with CSF-1R inhibitor (PLX5622). Eight mice per group were used for N,N -diethyl-2-(2-(4-(2-
18 F-fluoroethoxy) phenyl)5,7dimethylpyrazolo[1, 5a]pyrimidin-3-yl)acetamide (18 F-DPA-714) (TSPO) PET imaging on days 7, 14, 21, and 30 after ischemia and behavioral tests before and after surgery. An extra group of 8 mice underwent MRI, including T2-weighted (infarct), perfusion-weighted (cerebral blood flow), and diffusion-weighted (water diffusion, cellular density) sequences, on days 1, 3, 7, 14, 21, and 30. Ex vivo analysis (immunoreactivity, gene expression) was performed to characterize the inflammatory environment. Results: We demonstrated that long-term CSF-1R inhibition transiently decreased the TSPO PET signal within the infarct. Residual TSPO activity was partly due to a potentially resistant Iba-1-positive cell populations with low CSF-1R and transmembrane 119 expression. The decrease in selected pro- and antiinflammatory marker expression suggested an apparent global dampening of the neuroinflammatory response. Furthermore, the temporal changes in the MRI parameters highlighted treatment-induced effects on reperfusion and tissue homeostasis, associated with impaired motor function at late stages. Conclusion: Longitudinal TSPO PET/MRI allows the assessment of target engagement and optimization of drug efficiency. PLX5622 has promising immunomodulatory effects, and the optimal therapeutic time window for its application needs to be defined., (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2022
- Full Text
- View/download PDF
36. Combined Fluorescence-Guided Resection and Intracavitary Thermotherapy with Superparamagnetic Iron-Oxide Nanoparticles for Recurrent High-Grade Glioma: Case Series with Emphasis on Complication Management.
- Author
-
Schwake M, Müther M, Bruns AK, Zinnhardt B, Warneke N, Holling M, Schipmann S, Brokinkel B, Wölfer J, Stummer W, and Grauer O
- Abstract
Background: Concepts improving local tumor control in high-grade glioma (HGG) are desperately needed. The aim of this study is to report an extended series of cases treated with a combination of 5-ALA-fluorescence-guided resection (FGR) and intracavitary thermotherapy with superparamagnetic iron oxide nanoparticles (SPION)., Methods: We conducted a single-center retrospective review of all recurrent HGG treated with FGR and intracavitary thermotherapy ( n = 18). Patients underwent six hyperthermia sessions in an alternating magnetic field and received additional adjuvant therapies on a case-by-case basis., Results: Nine patients were treated for first tumor recurrence; all other patients had suffered at least two recurrences. Nine patients received combined radiotherapy and thermotherapy. The median progression-free survival was 5.5 (95% CI: 4.67-6.13) months and median overall survival was 9.5 (95% CI: 7.12-11.79) months. No major side effects were observed during active treatment. Thirteen patients (72%) developed cerebral edema and more clinical symptoms during follow-up and were initially treated with dexamethasone. Six (33%) of these patients underwent surgical removal of nanoparticles due to refractory edema., Conclusions: The combination of FGR and intracavitary thermotherapy with SPION provides a new treatment option for improving local tumor control in recurrent HGG. The development of cerebral edema is a major issue requiring further refinements of the treatment protocol.
- Published
- 2022
- Full Text
- View/download PDF
37. Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.
- Author
-
Barca C, Griessinger CM, Faust A, Depke D, Essler M, Windhorst AD, Devoogdt N, Brindle KM, Schäfers M, Zinnhardt B, and Jacobs AH
- Abstract
Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.
- Published
- 2021
- Full Text
- View/download PDF
38. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
- Author
-
Müther M, Roll W, Brokinkel B, Zinnhardt B, Sporns PB, Seifert R, Schäfers M, Weckesser M, Stegger L, Stummer W, and Rahbar K
- Subjects
- Humans, Female, Middle Aged, Male, Aged, Retrospective Studies, Treatment Outcome, Disease Progression, Molecular Targeted Therapy, Magnetic Resonance Imaging, Radiopharmaceuticals therapeutic use, Positron-Emission Tomography, Meningioma radiotherapy, Meningioma diagnostic imaging, Meningioma metabolism, Receptors, Somatostatin metabolism, Octreotide analogs & derivatives, Octreotide therapeutic use, Meningeal Neoplasms radiotherapy, Meningeal Neoplasms diagnostic imaging, Meningeal Neoplasms metabolism, Organometallic Compounds therapeutic use
- Abstract
Background: In somatostatin receptor (SSTR) expressing progressive meningioma, peptide receptor radionuclide therapy (PRRT) has shown effect in small clinical series. However, standardized treatment and response assessment protocols are lacking. We present our experience on PPRT with
177 Lu-DOTATATE in progressive meningioma with a special emphasis on state-of-the-art response assessment., Methods: Retrospective analysis on PRRT with177 Lu-DOTATATE from 2015 to 2019. Pre- and post-therapy imaging was performed using MRI and68 Ga-DOTATATE-PET for standard bidimensional and volumetric analyses, respectively, following novel RANO guidelines., Results: Seven patients with progressive intracranial meningioma (median age 73 years, interquartile range 60-76; 5 WHO II, 2 WHO I; 5 multifocal) received a median of 4 cycles 2 3 4 of PRRT with177 Lu-DOTATATE in eight-week intervals. Three patients did not undergo post-therapy68 Ga-DOTATATE-PET due to early symptomatic progression and subsequent cessation of PRRT. After completion of 4 PRRT cycles volumetric PET imaging showed stable disease in two of four patients. According to bidimensional MRI response assessment, only one patient was stable. Progression free survival at six months was 42.9 %., Conclusion: In this heterogeneous collective of seven patients with progressive meningioma, 177Lu-DOTATATE therapies showed heterogeneous effectiveness. PET-based volumetric assessment should be used for response assessment in PRRT additionally to bidimensional imaging., Competing Interests: The authors declare that they have no conflict of interest., (© Georg Thieme Verlag KG Stuttgart · New York.)- Published
- 2020
- Full Text
- View/download PDF
39. Correction to: Multimodal Molecular Imaging of the Tumour Microenvironment.
- Author
-
Foray C, Barca C, Backhaus P, Schelhaas S, Winkeler A, Viel T, Schäfers M, Grauer O, Jacobs AH, and Zinnhardt B
- Published
- 2020
- Full Text
- View/download PDF
40. Multimodal Molecular Imaging of the Tumour Microenvironment.
- Author
-
Foray C, Barca C, Backhaus P, Schelhaas S, Winkeler A, Viel T, Schäfers M, Grauer O, Jacobs AH, and Zinnhardt B
- Subjects
- Humans, Immunotherapy, Neoplasms immunology, Neoplasms metabolism, Neoplasms pathology, Molecular Imaging, Neoplasms therapy, Tumor Microenvironment drug effects
- Abstract
The tumour microenvironment (TME) surrounding tumour cells is a highly dynamic and heterogeneous composition of immune cells, fibroblasts, precursor cells, endothelial cells, signalling molecules and extracellular matrix (ECM) components. Due to the heterogeneity and the constant crosstalk between the TME and the tumour cells, the components of the TME are important prognostic parameters in cancer and determine the response to novel immunotherapies. To improve the characterization of the TME, novel non-invasive imaging paradigms targeting the complexity of the TME are urgently needed.The characterization of the TME by molecular imaging will (1) support early diagnosis and disease follow-up, (2) guide (stereotactic) biopsy sampling, (3) highlight the dynamic changes during disease pathogenesis in a non-invasive manner, (4) help monitor existing therapies, (5) support the development of novel TME-targeting therapies and (6) aid stratification of patients, according to the cellular composition of their tumours in correlation to their therapy response.This chapter will summarize the most recent developments and applications of molecular imaging paradigms beyond FDG for the characterization of the dynamic molecular and cellular changes in the TME.
- Published
- 2020
- Full Text
- View/download PDF
41. TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma.
- Author
-
Pigeon H, Pérès EA, Truillet C, Jego B, Boumezbeur F, Caillé F, Zinnhardt B, Jacobs AH, Le Bihan D, and Winkeler A
- Subjects
- Animals, Apoptosis, Brain Neoplasms diagnostic imaging, Brain Neoplasms metabolism, Cell Proliferation, Glioma diagnostic imaging, Glioma metabolism, Humans, Male, Mice, Mice, Nude, Neoplasm Invasiveness, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Brain Neoplasms pathology, Diffusion Magnetic Resonance Imaging methods, Fluorine Radioisotopes metabolism, Glioma pathology, Positron-Emission Tomography methods, Pyrazoles metabolism, Pyrimidines metabolism, Receptors, GABA metabolism
- Abstract
Background: Glioblastoma (GBM) is the most devastating brain tumor. Despite the use of multimodal treatments, most patients relapse, often due to the highly invasive nature of gliomas. However, the detection of glioma infiltration remains challenging. The aim of this study was to assess advanced PET and MRI techniques for visualizing biological activity and infiltration of the tumor., Methods: Using multimodality imaging, we investigated [18F]DPA-714, a radiotracer targeting the 18 kDa translocator protein (TSPO), [18F]FET PET, non-Gaussian diffusion MRI (apparent diffusion coefficient, kurtosis), and the S-index, a composite diffusion metric, to detect tumor infiltration in a human invasive glioma model. In vivo imaging findings were confirmed by autoradiography and immunofluorescence., Results: Increased tumor-to-contralateral [18F]DPA-714 uptake ratios (1.49 ± 0.11) were found starting 7 weeks after glioma cell implantation. TSPO-PET allowed visualization of glioma infiltration into the contralateral hemisphere 2 weeks earlier compared with the clinically relevant biomarker for biological glioma activity [18F]FET. Diffusion-weighted imaging (DWI), in particular kurtosis, was more sensitive than standard T2-weighted MRI to detect differences between the glioma-bearing and the contralateral hemisphere at 5 weeks. Immunofluorescence data reflect in vivo findings. Interestingly, labeling for tumoral and stromal TSPO indicates a predominant expression of TSPO by tumor cells., Conclusion: These results suggest that advanced PET and MRI methods, such as [18F]DPA-714 and DWI, may be superior to standard imaging methods to visualize glioma growth and infiltration at an early stage., (© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
42. Molecular Imaging of Immune Cell Dynamics During De- and Remyelination in the Cuprizone Model of Multiple Sclerosis by [ 18 F]DPA-714 PET and MRI.
- Author
-
Zinnhardt B, Belloy M, Fricke IB, Orije J, Guglielmetti C, Hermann S, Wagner S, Schäfers M, Van der Linden A, and Jacobs AH
- Subjects
- Animals, Brain diagnostic imaging, Brain metabolism, Cuprizone toxicity, Female, Fluorine Radioisotopes, Magnetic Resonance Imaging, Mice, Mice, Inbred C57BL, Multiple Sclerosis etiology, Multiple Sclerosis immunology, Myelin Sheath metabolism, Multiple Sclerosis diagnostic imaging, Neuroglia immunology, Positron-Emission Tomography, Pyrazoles pharmacokinetics, Pyrimidines pharmacokinetics, Radiopharmaceuticals pharmacokinetics
- Abstract
Background : Activation and dysregulation of innate, adaptive and resident immune cells in response to damage determine the pathophysiology of demyelinating disorders. Among the plethora of involved cells, microglia/macrophages and astrocytes play an important role in the pathogenesis of demyelinating disorders. The in-depth investigation of the spatio-temporal profile of these cell types in vivo may inform about the exact disease state and localization as well as may allow to monitor therapeutic modulation of the components of the neuroinflammatory response during the course of multiple sclerosis (MS). In this study, we aimed to non-invasively decipher the degree and temporal profile of neuroinflammation (TSPO - [
18 F]DPA-714 PET) in relation to selected magnetic resonance imaging (MRI) parameters (T2 maps) in the cuprizone (CPZ)-induced model of demyelination. Methods: C57Bl6 ( n=30 ) mice were fed with a standard chow mixed with 0.2% (w/w) CPZ for 4 ( n=10 ; demyelination) and 6 weeks ( n=10 ; spontaneous remyelination). The degree of neuroinflammation at de- and remyelination was assessed by [18 F]DPA-714 PET, multi-echo T2 MRI, autoradiography and immunohistochemistry. Results : CPZ-induced brain alterations were confirmed by increase of T2 relaxation times in both white and grey matter after 3 and 5 weeks of CPZ. Peak [18 F]DPA-714 was found in the corpus callosum (CC, white matter), the hippocampus (HC, grey matter) and thalamus (grey matter) after 4 weeks of CPZ treatment and declined after 6 weeks of CPZ. Ex vivo autoradiography and dedicated immunofluorescence showed demyelination/remyelination with corresponding increased/decreased TSPO levels in the CC and hippocampus, confirming the spatial distribution of [18 F]DPA-714 in vivo . The expression of TSPO microglia and astrocytes is time-dependent in this model. Microglia predominantly express TSPO at demyelination, while the majority of astrocytes express TSPO during remyelination. The combination of PET- and MRI-based imaging biomarkers demonstrated the regional and temporal development of the CPZ model-associated neuroinflammatory response in grey and white matter regions. Conclusions : The combination of [18 F]DPA-714 PET and T2 mapping may allow to further elucidate the regional and temporal profile of inflammatory signals depending on the myelination status, although the underlying inflammatory microenvironment changes. A combination of the described imaging biomarkers may facilitate the development of patient-tailored strategies for immunomodulatory and neuro-restorative therapies in MS., Competing Interests: Competing Interests: The authors have declared that no competing interest exists.- Published
- 2019
- Full Text
- View/download PDF
43. Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation state.
- Author
-
Villa A, Klein B, Janssen B, Pedragosa J, Pepe G, Zinnhardt B, Vugts DJ, Gelosa P, Sironi L, Beaino W, Damont A, Dollé F, Jego B, Winkeler A, Ory D, Solin O, Vercouillie J, Funke U, Laner-Plamberger S, Blomster LV, Christophersen P, Vegeto E, Aigner L, Jacobs A, Planas AM, Maggi A, and Windhorst AD
- Subjects
- Animals, Anti-Inflammatory Agents administration & dosage, Carbon Radioisotopes administration & dosage, Computational Biology, Gene Expression Profiling, Humans, Immunohistochemistry, Interleukin-4 administration & dosage, Mice, Radioactive Tracers, Real-Time Polymerase Chain Reaction, Receptors, Purinergic P2Y12 analysis, Rodentia, Stroke pathology, Brain diagnostic imaging, Brain immunology, Microglia immunology, Molecular Imaging methods, Positron-Emission Tomography methods
- Abstract
Microglia are potential targets for therapeutic intervention in neurological and neurodegenerative diseases affecting the central nervous system. In order to assess the efficacy of therapies aimed to reduce the tissue damaging activities of microglia and/or to promote the protective potential of these cells, suitable pre-clinical and clinical tools for the in vivo analysis of microglia activities and dynamics are required. The aim of this work was to identify new translational markers of the anti-inflammatory / protective state of microglia for the development of novel PET tracers. Methods: New translational markers of the anti-inflammatory/protective activation state of microglia were selected by bioinformatic approaches and were in vitro and ex vivo validated by qPCR and immunohistochemistry in rodent and human samples. Once a viable marker was identified, a novel PET tracer was developed. This tracer was subsequently confirmed by autoradiography experiments in murine and human brain tissues. Results: Here we provide evidence that P2RY12 expression increases in murine and human microglia following exposure to anti-inflammatory stimuli, and that its expression is modulated in the reparative phase of experimental and clinical stroke. We then synthesized a novel carbon-11 labeled tracer targeting P2RY12, showing increased binding in brain sections of mice treated with IL4, and low binding to brain sections of a murine stroke model and of a stroke patient. Conclusion: This study provides new translational targets for PET tracers for the anti-inflammatory/protective activation state of microglia and shows the potential of a rationale-based approach. It therefore paves the way for the development of novel non-invasive methodologies aimed to monitor the success of therapeutic approaches in various neurological diseases., Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
- Published
- 2018
- Full Text
- View/download PDF
44. In vivo imaging biomarkers of neuroinflammation in the development and assessment of stroke therapies - towards clinical translation.
- Author
-
Zinnhardt B, Wiesmann M, Honold L, Barca C, Schäfers M, Kiliaan AJ, and Jacobs AH
- Subjects
- Animals, Biomarkers metabolism, Humans, Positron-Emission Tomography methods, Radiopharmaceuticals administration & dosage, Radiopharmaceuticals adverse effects, Radiopharmaceuticals pharmacokinetics, Stroke drug therapy, Translational Research, Biomedical, Anti-Inflammatory Agents therapeutic use, Stroke diagnostic imaging, Theranostic Nanomedicine methods
- Abstract
Modulation of the inflammatory microenvironment after stroke opens a new avenue for the development of novel neurorestorative therapies in stroke. Understanding the spatio-temporal profile of (neuro-)inflammatory imaging biomarkers in detail thereby represents a crucial factor in the development and application of immunomodulatory therapies. The early integration of quantitative molecular imaging biomarkers in stroke drug development may provide key information about (i) early diagnosis and follow-up, (ii) spatio-temporal drug-target engagement (pharmacodynamic biomarker), (iii) differentiation of responders and non-responders in the patient cohort (inclusion/exclusion criteria; predictive biomarkers), and (iv) the mechanism of action. The use of targeted imaging biomarkers for may thus allow clinicians to decipher the profile of patient-specific inflammatory activity and the development of patient-tailored strategies for immunomodulatory and neuro-restorative therapies in stroke. Here, we highlight the recent developments in preclinical and clinical molecular imaging biomarkers of neuroinflammation (endothelial markers, microglia, MMPs, cell labeling, future developments) in stroke and outline how imaging biomarkers can be used in overcoming current translational roadblocks and attrition in order to advance new immunomodulatory compounds within the clinical pipeline., Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
- Published
- 2018
- Full Text
- View/download PDF
45. Combined PET Imaging of the Inflammatory Tumor Microenvironment Identifies Margins of Unique Radiotracer Uptake.
- Author
-
Zinnhardt B, Pigeon H, Thézé B, Viel T, Wachsmuth L, Fricke IB, Schelhaas S, Honold L, Schwegmann K, Wagner S, Faust A, Faber C, Kuhlmann MT, Hermann S, Schäfers M, Winkeler A, and Jacobs AH
- Subjects
- Animals, Brain Neoplasms metabolism, Brain Neoplasms pathology, Female, Fluorine Radioisotopes, Glioma metabolism, Glioma pathology, Matrix Metalloproteinases metabolism, Mice, Mice, Nude, Microglia pathology, Positron-Emission Tomography, Radiopharmaceuticals, Receptors, GABA metabolism, Tumor Microenvironment, Brain Neoplasms diagnostic imaging, Glioma diagnostic imaging
- Abstract
The tumor microenvironment is highly heterogeneous. For gliomas, the tumor-associated inflammatory response is pivotal to support growth and invasion. Factors of glioma growth, inflammation, and invasion, such as the translocator protein (TSPO) and matrix metalloproteinases (MMP), may serve as specific imaging biomarkers of the glioma microenvironment. In this study, noninvasive imaging by PET with [
18 F]DPA-714 (TSPO) and [18 F]BR-351 (MMP) was used for the assessment of localization and quantification of the expression of TSPO and MMP. Imaging was performed in addition to established clinical imaging biomarker of active tumor volume ([18 F]FET) in conjunction with MRI. We hypothesized that each imaging biomarker revealed distinct areas of the heterogeneous glioma tissue in a mouse model of human glioma. Tracers were found to be increased 1.4- to 1.7-fold, with [18 F]FET showing the biggest volume as depicted by a thresholding-based, volumes of interest analysis. Tumor areas, which could not be detected by a single tracer and/or MRI parameter alone, were measured. Specific compartments of [18 F]DPA-714 (14%) and [18 F]BR-351 (11%) volumes along the tumor rim could be identified. [18 F]DPA-714 (TSPO) and [18 F]BR-351 (MMP) matched with histology. Glioma-associated microglia/macrophages (GAM) were identified as TSPO and MMP sources. Multitracer and multimodal molecular imaging approaches may allow us to gain important insights into glioma-associated inflammation (GAM, MMP). Moreover, this noninvasive technique enables characterization of the glioma microenvironment with respect to the disease-driving cellular compartments at the various disease stages. Cancer Res; 77(8); 1831-41. ©2017 AACR ., (©2017 American Association for Cancer Research.)- Published
- 2017
- Full Text
- View/download PDF
46. A specific dietary intervention to restore brain structure and function after ischemic stroke.
- Author
-
Wiesmann M, Zinnhardt B, Reinhardt D, Eligehausen S, Wachsmuth L, Hermann S, Dederen PJ, Hellwich M, Kuhlmann MT, Broersen LM, Heerschap A, Jacobs AH, and Kiliaan AJ
- Subjects
- Animals, Behavior, Animal, Disease Models, Animal, Locomotion, Magnetic Resonance Imaging, Male, Mice, Mice, Inbred C57BL, Positron-Emission Tomography, Stroke diagnostic imaging, Stroke pathology, Treatment Outcome, Diet Therapy methods, Docosahexaenoic Acids administration & dosage, Eicosapentaenoic Acid administration & dosage, Phospholipids administration & dosage, Stroke therapy
- Abstract
Occlusion of the middle cerebral artery (MCAo) is among the most common causes of ischemic stroke in humans. Cerebral ischemia leads to brain lesions existing of an irreversibly injured core and an ischemic boundary zone, the penumbra, containing damaged but potentially salvageable tissue. Using a transient occlusion (30 min) of the middle cerebral artery (tMCAo) mouse model in this cross-institutional study we investigated the neurorestorative efficacy of a dietary approach (Fortasyn) comprising docosahexaenoic acid, eicosapentaenoic acid, uridine, choline, phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium as therapeutic approach to counteract neuroinflammation and impairments of cerebral (structural+functional) connectivity, cerebral blood flow (CBF), and motor function. Male adult C57BL/6j mice were subjected to right tMCAo using the intraluminal filament model. Following tMCAo, animals were either maintained on Control diet or switched to the multicomponent Fortasyn diet. At several time points after tMCAo, behavioral tests, and MRI and PET scanning were conducted to identify the impact of the multicomponent diet on the elicited neuroinflammatory response, loss of cerebral connectivity, and the resulting impairment of motor function after experimental stroke. Mice on the multicomponent diet showed decreased neuroinflammation, improved functional and structural connectivity, beneficial effect on CBF, and also improved motor function after tMCAo. Our present data show that this specific dietary intervention may have beneficial effects on structural and functional recovery and therefore therapeutic potential after ischemic stroke., Competing Interests: Competing Interests: Laus M. Broersen is employed by Nutricia Research. No actual or potential competing interests apply for the remaining authors. Nutricia Research was neither involved in data analyses, statistical analyses, nor writing the manuscript.
- Published
- 2017
- Full Text
- View/download PDF
47. Multimodal Imaging of Patients With Gliomas Confirms 11 C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy.
- Author
-
Laukamp KR, Lindemann F, Weckesser M, Hesselmann V, Ligges S, Wölfer J, Jeibmann A, Zinnhardt B, Viel T, Schäfers M, Paulus W, Stummer W, Schober O, and Jacobs AH
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Humans, Logistic Models, Middle Aged, Neoplasm Grading, Retrospective Studies, Young Adult, Glioma diagnostic imaging, Magnetic Resonance Imaging methods, Multimodal Imaging methods, Positron-Emission Tomography methods
- Abstract
The value of combined L-( methyl-[
11 C]) methionine positron-emitting tomography (MET-PET) and magnetic resonance imaging (MRI) with regard to tumor extent, entity prediction, and therapy effects in clinical routine in patients with suspicion of a brain tumor was investigated. In n = 65 patients with histologically verified brain lesions n = 70 MET-PET and MRI (T1-weighted gadolinium-enhanced [T1w-Gd] and fluid-attenuated inversion recovery or T2-weighted [FLAIR/T2w]) examinations were performed. The computer software "visualization and analysis framework volume rendering engine (Voreen)" was used for analysis of extent and intersection of tumor compartments. Binary logistic regression models were developed to differentiate between World Health Organization (WHO) tumor types/grades. Tumor sizes as defined by thresholding based on tumor-to-background ratios were significantly different as determined by MET-PET (21.6 ± 36.8 cm3 ), T1w-Gd-MRI (3.9 ± 7.8 cm3 ), and FLAIR/T2-MRI (64.8 ± 60.4 cm3 ; P < .001). The MET-PET visualized tumor activity where MRI parameters were negative: PET positive tumor volume without Gd enhancement was 19.8 ± 35.0 cm3 and without changes in FLAIR/T2 10.3 ± 25.7 cm3 . FLAIR/T2-MRI visualized greatest tumor extent with differences to MET-PET being greater in posttherapy (64.6 ± 62.7 cm3 ) than in newly diagnosed patients (20.5 ± 52.6 cm3 ). The binary logistic regression model differentiated between WHO tumor types (fibrillary astrocytoma II n = 10 from other gliomas n = 16) with an accuracy of 80.8% in patients at primary diagnosis. Combined PET and MRI improve the evaluation of tumor activity, extent, type/grade prediction, and therapy-induced changes in patients with glioma and serve information highly relevant for diagnosis and management.- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.